Lorazepam can be given by several routes, including oral, sublingual (under the tongue), intravenous, intramuscular, and intranasal, with each route offering close to complete absorption into the bloodstream but differing in how quickly the drug takes effect. The route your clinician chooses depends on the clinical situation, whether you can swallow, how fast the drug needs to work, and what equipment is available. The pharmacology of each route is well studied, but the practical trade-offs are more nuanced than a simple ranking of speed.
Oral Administration
Swallowing a lorazepam tablet is the most common route for anxiety, insomnia, and scheduled dosing before procedures. The drug is absorbed quickly after it hits the stomach and small intestine, with an absorption half-life of roughly 15 minutes in younger adults and peak blood levels typically reached within about two hours. That peak lines up with the time point at which sedation and anxiety relief feel strongest. Once absorbed, lorazepam is almost entirely available to the body, with bioavailability consistently measured at 80 to 100 percent, meaning very little of the dose is lost to first-pass metabolism in the liver.1PubMed. Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam The elimination half-life after an oral dose is around 12 hours, though individual variation exists.
In older adults, oral absorption remains reliable. Studies in elderly volunteers still showed peak plasma concentrations reached within two and a half hours, with absorption 80 to 100 percent complete.2PubMed. Lorazepam kinetics in the elderly This predictability is part of why lorazepam is often preferred over longer-acting benzodiazepines in older patients: the drug does not rely on the complex liver enzyme pathways that slow down with age. Instead, it is cleared mainly through a simple metabolic step called glucuronidation, which stays relatively intact even in people with liver disease or advanced age.3Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Benzodiazepines for Alcohol Withdrawal in the Elderly and in Patients With Liver Disease
Sublingual Administration
Placing a tablet under the tongue lets lorazepam absorb through the mucous membranes without needing to pass through the stomach. This route is particularly useful for people who are nauseated, vomiting, or otherwise unable to swallow. A pharmacokinetic comparison found that sublingual lorazepam reaches full systemic availability, averaging about 94 to 98 percent, and the absorption half-life is slightly faster than oral dosing, around 28 to 29 minutes versus about 33 minutes for a swallowed tablet.4PubMed. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam A multi-dose study confirmed this pattern, estimating the sublingual absorption half-life at about 15 minutes compared with 55 minutes for the oral formulation.5PubMed. Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses
More recently, sublingual lorazepam has been studied as a rescue therapy for seizure emergencies in adults. In a trial of patients experiencing repetitive or prolonged seizures, about two-thirds of those with repetitive seizures had no further seizure activity after sublingual dosing, and 70 percent of those with prolonged seizures saw activity stop within five minutes of treatment.6PubMed. Sublingual lorazepam as rescue therapy for seizure emergencies in adults This matters because it suggests the sublingual route could serve as a practical option outside of hospital settings, where intravenous access is not available.
Intravenous Administration
An IV line delivers lorazepam directly into the bloodstream, which is the standard approach in hospital emergencies like status epilepticus or acute agitation. You might expect IV delivery to produce the fastest onset of any route, and in terms of reaching peak blood levels, it does. But lorazepam has an unusual quirk compared with some other benzodiazepines: its entry into the brain is relatively slow. Research using EEG monitoring showed that the maximum change in brain-wave activity did not occur until about 30 minutes after IV infusion. Animal studies confirmed that the brain-to-blood concentration ratio for lorazepam was still equilibrating at least 30 minutes after the dose, whereas a comparable drug reached its brain peak within a few minutes.7PubMed. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam
This slow brain-entry profile has real clinical consequences. In an active seizure, clinicians sometimes observe that a competing drug given IV will stop a convulsion faster, even though lorazepam ultimately provides longer-lasting seizure protection. The trade-off is deliberate: lorazepam’s slower brain penetration also means it stays effective longer, reducing the chance of seizures returning. For pre-procedure sedation and anxiety management in the emergency department, the 20-to-30-minute onset is usually fine because those situations are not as time-critical as active convulsions.
Intramuscular Administration
Intramuscular injection of lorazepam into the deltoid muscle produces rapid, reliable absorption. After a single injection, peak concentrations are typically reached within about two to three hours, with an absorption half-life of around 21 minutes and near-complete bioavailability.8PubMed Central. Clinical pharmacokinetics of lorazepam. II. Intramuscular injection This is a meaningful advantage over many other benzodiazepines given intramuscularly: some of them are absorbed erratically from muscle tissue, leading to unpredictable blood levels and unreliable clinical effects.
Lorazepam’s predictable IM absorption makes it a strong choice when IV access is difficult or impossible. In alcohol withdrawal management, for instance, patients are sometimes too agitated or combative for an IV to be placed safely. IM lorazepam can be given quickly and reliably in that setting.9Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Benzodiazepines for Alcohol Withdrawal in the Elderly and in Patients With Liver Disease In children with severe convulsions, a study found that IM lorazepam achieved therapeutic concentrations within a median of 25 minutes and maintained those levels for at least 8 hours, with 91 percent of children treated IM remaining seizure-free for over 72 hours. No clinically apparent respiratory depression was seen.10PubMed Central. Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions One downside: IM injection can be painful at the site, a consideration that matters more in pediatrics and repeated dosing.
Intranasal Administration
Giving lorazepam through the nose is not a standard approved route, but it has been studied as a potential option for emergencies where neither IV access nor oral administration is feasible. The research on intranasal bioavailability is somewhat conflicting. One study reported a mean bioavailability of about 78 percent, with intranasal delivery actually producing a faster absorption rate than the intramuscular route. Some subjects showed a double-peak pattern in their blood levels, suggesting that part of the dose dripped into the throat and was absorbed orally.11PubMed. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration An earlier study was less optimistic, finding bioavailability ranging from only 35 to 63 percent and concluding that the intranasal route had limited potential for acute seizure treatment.12International Journal of Pharmaceutics. Absorption of diazepam and lorazepam following intranasal administration
The inconsistency between these results likely reflects differences in formulation, the volume of solution deposited in the nose, and how much of the dose was swallowed rather than absorbed through the nasal mucosa. Intranasal lorazepam remains investigational rather than a recommended route, though the concept continues to attract interest for prehospital seizure management, where other benzodiazepines already have approved nasal formulations.
Rectal Administration
Rectal dosing of lorazepam has been explored primarily for seizure control in settings where other routes are impractical, particularly in young children. However, rectal absorption is notably slower than other routes, with time to peak concentration estimated at one to two hours.13PubMed Central. Intramuscular and rectal therapies of acute seizures That sluggish uptake is a serious drawback for seizure emergencies, where every minute of ongoing convulsive activity can cause harm. For this reason, when rectal administration is the only option, clinicians often prefer a different benzodiazepine that absorbs more quickly by that route. Rectal lorazepam might still be considered in palliative or end-of-life care when other access points are unavailable and speed of onset is less critical.
Propylene Glycol and IV Infusion Safety
The injectable form of lorazepam uses propylene glycol as a solvent, which creates a safety concern that is unique to the IV route and irrelevant to oral or sublingual dosing. When lorazepam is given as a continuous IV infusion, propylene glycol accumulates in the body. A prospective study of ICU patients found that about one in five patients receiving IV lorazepam or diazepam showed metabolic signs of propylene glycol toxicity.14PubMed. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines The condition can cause a type of metabolic acidosis, kidney injury, and other complications that mimic organ failure from the patient’s underlying illness, making it easy to miss.
Research specifically tracking propylene glycol accumulation found a strong relationship between the infusion rate, the total 24-hour lorazepam dose, and the resulting propylene glycol concentration in the blood. Patients with pre-existing kidney problems were at higher risk.15PubMed. Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions Another study documented that kidney function markers worsened in all eight patients receiving prolonged lorazepam infusions and improved within days of stopping. The duration of the infusion showed the strongest link to the degree of kidney impairment.16PubMed. Propylene glycol-associated renal toxicity from lorazepam infusion
This toxicity risk is why many ICUs have moved toward alternatives for continuous sedation in critically ill patients, reserving IV lorazepam for intermittent bolus dosing or short-term use. Monitoring osmol gaps and serum lactate can help catch propylene glycol accumulation early. In pediatric patients, the same concern applies: sustained infusion in children can cause progressive accumulation of propylene glycol.17Journal of Clinical Case Reports and Studies. Clinical pharmacology of lorazepam in infants and children
Drug Stability in IV Bags and Tubing
Beyond propylene glycol, there is a practical formulation issue that matters for hospitals preparing lorazepam drips. When lorazepam is mixed into standard IV bags made of polyvinyl chloride (PVC), the drug gradually sticks to the plastic. Studies have documented significant loss of lorazepam from PVC bag solutions stored in both common diluents, at both room temperature and refrigerated conditions.18PubMed. Lorazepam stability in parenteral solutions for continuous intravenous administration The loss follows a predictable pattern that accounts for both the drug binding to the PVC surface and the changing ratio of surface area to remaining solution as the bag empties.19PubMed. Lorazepam solubility in and sorption from intravenous admixture solutions
The practical takeaway is that a patient receiving a lorazepam drip from a PVC bag may get less drug than intended, especially if the solution has been sitting for hours. Pharmacies manage this by using glass containers or non-PVC bags when available, preparing fresh admixtures at shorter intervals, and accounting for known sorption losses when calculating infusion concentrations. It sounds like a minor logistics problem, but in an ICU patient being sedated for mechanical ventilation, an unexpected drop in delivered dose can mean inadequate sedation or unnecessary dose escalation.
How Route Choice Differs in Children
In pediatric patients, the most commonly used route is slow IV infusion over three to five minutes, typically dosed at around 0.1 mg per kilogram of body weight up to a maximum of 4 mg. Population pharmacokinetic modeling in children with status epilepticus found that this standard dosing approach reliably produces blood concentrations in the range associated with effective seizure control.20PubMed Central. Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus Children do clear the drug somewhat differently than adults: younger children tend to have slightly higher weight-adjusted clearance rates, and the elimination half-life in infants and children ranges from roughly 15 to 18 hours, somewhat longer than in adults.21Journal of Clinical Case Reports and Studies. Clinical pharmacology of lorazepam in infants and children
IM injection works well in children when IV access is not readily available, as demonstrated in the study of children with severe malaria-related convulsions. The relative bioavailability of IM lorazepam in that population was about 89 percent, and therapeutic concentrations were maintained for at least eight hours.22PubMed Central. Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions IM injection can be painful, however, so some clinicians prefer buccal or intranasal routes in children even though those alternatives are less well studied for lorazepam specifically. The rectal route, while an option, is generally less favored for lorazepam given its slow absorption compared with other benzodiazepines delivered rectally.
Liver Disease and Aging
One of lorazepam’s practical advantages over many competing benzodiazepines is that its metabolism does not depend heavily on liver enzymes that decline with age or disease. Most benzodiazepines undergo oxidative metabolism in the liver, a process that slows substantially in cirrhosis and in elderly patients, leading to prolonged sedation and accumulation. Lorazepam bypasses that pathway entirely, undergoing only glucuronidation, which remains relatively preserved even in significant liver disease.23Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Benzodiazepines for Alcohol Withdrawal in the Elderly and in Patients With Liver Disease This makes it a safer empiric choice when treating conditions like alcohol withdrawal in patients with cirrhosis or in older adults where unpredictable drug clearance could be dangerous.
That said, older adults are generally more sensitive to the sedative effects of all benzodiazepines, regardless of how the drug is metabolized. The pharmacokinetic predictability of lorazepam does not eliminate the pharmacodynamic reality that an elderly brain responds more strongly to the same blood concentration. Clinicians typically use lower doses in this population, and some guidelines recommend avoiding benzodiazepines altogether in older adults when alternatives exist.
When Route Choice Becomes a Clinical Decision
In practice, selecting a route for lorazepam is not about picking the “best” one in the abstract. It is about matching the route to the patient’s immediate circumstances. A person taking lorazepam for chronic anxiety at home will use oral tablets. Someone in the emergency department with active seizures who already has an IV will receive it intravenously. A combative patient in alcohol withdrawal with no IV access will get an IM injection in the deltoid. A patient who is vomiting may be given a sublingual tablet. Each of these routes delivers the drug effectively, but the time to onset, the peak concentration, and the logistical requirements differ enough to matter in urgent situations.
The roughly two-hour time to peak effect for oral and sublingual routes is acceptable for scheduled dosing but too slow for an active convulsion. IV delivery gets drug into the blood instantly but still takes up to 30 minutes to reach maximum brain effect, which is slower than some clinicians expect. IM injection offers a middle ground in terms of convenience and reliability but shares the same general timeframe. And intranasal delivery, while faster to absorb than IM in at least one study, has not yet been standardized enough for widespread clinical use with lorazepam.
Understanding these trade-offs helps explain decisions that might otherwise seem arbitrary. If you have ever wondered why a nurse gave you an injection when a pill seemed simpler, or why a doctor in the ER chose a different benzodiazepine for immediate seizure control but switched to lorazepam for ongoing protection, the pharmacokinetics of each route are the reason. The drug is the same molecule regardless of how it enters the body; the route just determines how quickly and reliably it gets where it needs to go.